Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
Indian Journal of Anaesthesia, doi:10.4103/ija.ija_149_21
Background and Aims: When the world was frantically searching for a drug effective against the coronavirus disease (COVID)-19, remdesivir, a broad-spectrum anti-viral medication, became a part of the COVID treatment. We planned a study to evaluate improvement in clinical outcomes with remdesivir treatment for five days. Methods: Participants more than 40-years old and with moderate to severe COVID-19 but not on mechanical ventilation were randomly assigned into two groups-remdesivir group (34 cases) to receive the study drug intravenous (IV) remdesivir for five days plus the standard care (SC) and non-remdesivir group (36 cases) to receive the SC but not to receive the study drug. Follow-up was continued for 12 days after the beginning of treatment or until discharge/death. Patient's clinical status was assessed by laboratory investigations and physical examination (from day 1 to day 12 on a 4-point ordinal scale and from day 12 to 24 on a 6-point ordinal scale). Oxygen support requirements and adverse events were recorded. The data were entered and analysed using Statistical Package for the Social Sciences (SPSS) version 22.0. Results: High-flow oxygen support and non-invasive ventilation was required at baseline by lesser patients in the remdesivir group. In the end, both groups had similar outcomes after adjustment for baseline clinical status. There was no statistical difference in mortality between the two groups (p = 0.749). Patients in both groups had an equal time to recovery. There was no difference in the occurrence of adverse effects of remdesivir between the two groups. Conclusion: Remdesivir therapy for five days did not produce improvement in clinical outcomes in moderate to severe COVID-19 cases.
Conflicts of interest There are no conflicts of interest.
Bajwa, Editing from the dungeons of the pandemic; An editor's agonisingly painful battle with COVID-19, Indian J Anaesth
Bajwa, Sarna, Bawa, Mehdiratta, Peri-operative and critical care concerns in corona virus pandemic, Indian J Anaesth
Biegel, Tomashek, Lori, Mehta, Barry et al., Remdesivir for the treatment of Covid -19 -Final Report, N Engl J Med
Fauci, Lane, Field Rr, Covid-19 -Navigating the uncharted, N Engl J Med
Goldman, David, Hui, Marks, Bruno et al., Remdesivir for 5 or 10 days in patients with severe Covid -19, N Engl J Med
Mulangu, Dodd, Jr, Mbaya, Proschan et al., A randomized, controlled trial of Ebola virus disease therapeutics, N Engl J Med
O'keeffe, Ambler, Barber, Sample size calculations based on a difference in medians for positively skewed outcomes in health care studies, BMC Med Res Methodol, doi:10.1186/s12874-017-0426-1
Spinner, Gottlieb, Criner, Lopez, Cattelan et al., Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial, JAMA
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Zhang, Guanhua, Ronghui, Zhao et al., Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicenter trial, Lancet
Williamson, Feldmann, Schwarz, Meade-White, Porter et al., Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2, bioRxiv, doi:10.1101/2020.04.15.043166